Team:Freiburg Bioware/Project/insertion of motifs into surface-exposed loops

From 2010.igem.org

(Difference between revisions)
(New page: <div align=center> <table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0 style='margin-left:180.8pt;border-collapse:collapse;border:none'> <tr style='height:142.35pt'> <td wi...)
 
(7 intermediate revisions not shown)
Line 1: Line 1:
-
<div align=center>
+
{{:Team:Freiburg_Bioware/Head}}
 +
{{:Team:Freiburg_Bioware/jquery}}
 +
{{:Team:Freiburg_Bioware/menu_home}}
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
+
<html>
-
style='margin-left:180.8pt;border-collapse:collapse;border:none'>
+
<head>
-
<tr style='height:142.35pt'>
+
</head>
-
  <td width=400 valign=top style='width:300.3pt;padding:0cm 5.4pt 0cm 5.4pt;
+
<body>
-
  height:142.35pt'>
+
<h1>Loop Insertion</h1>
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><img
+
<h2>Modification of the Viral Capsid of the AAV2 using Viral Bricks</h2>
-
  width=395 height=198 src="!Word%20-%20for%20mergeII-Dateien/image001.gif"
+
<p style="text-align: justify; margin-top: 10px;">
-
  align=left hspace=12 alt="Viral Bricks His.png"></p>
+
For therapeutical applications in human gene transfer, the broad tropism for heparan sulfate proteoglycan (HSPG) has to be knocked-out and a novel tropism has to be inserted.
-
  </td>
+
This retargeting can be achieved either by insertion of functional motifs into the two major surface exposed loops or by fusion of these motifs to the N-terminus of the viral coat proteins.
-
</tr>
+
The graphic on the right shows parts of the three-dimensional structure of a viral coat protein. The parts of the loop regions that are coded in the ViralBricks are shown in purple for the 453 loop and in blue for the 587 loop.
-
<tr style='height:22.6pt'>
+
</p>
-
  <td width=400 valign=top style='width:300.3pt;padding:0cm 5.4pt 0cm 5.4pt;
+
<img style="border: 0px solid ; width: 571px; height: 269px;" alt="" id="Picture 15"
-
  height:22.6pt'>
+
src="https://static.igem.org/mediawiki/2010/8/8f/Freiburg10_loop_insertion_sites.png">
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
<p style="font-size: 11px;">Three-dimensional representation of the AAV2 showing the amino acids of the 453 and 587 loops that are coded by the corresponding Viral Bricks.</p>
-
  lang=EN-US style='line-height:200%'>Schematic figure of His-affinity Tag
+
<h2>Cloning of Viral Bricks into capsid coding parts</h2>
-
  insertion into the viral capsid</span></p>
+
<p>In order to make loop insertions more convenient the following restriction sites were inserted into all capsid coding parts and already existing restriction sites were removed from the constructs. The choice of these restriction sites was reasoned by enzyme performance, buffer compatibilities and the number of existing restriction sites that had to be removed at other positions.
-
  </td>
+
All restriction endonucleases were purchased from NEB.
-
</tr>
+
</p>
 +
<img src="https://static.igem.org/mediawiki/2010/7/73/Freiburg_10_Bioware_Table.png" style="margin-bottom: 30px;"/>
 +
<h1>His-Affinity tag</h1>
 +
<div align="center">
 +
<table class="MsoTableGrid"
 +
style="border: medium none ; margin-left: 180.8pt; border-collapse: collapse;"
 +
border="0" cellpadding="0" cellspacing="0">
 +
<tbody>
 +
<tr style="height: 142.35pt;">
 +
<td style="padding: 0cm 5.4pt; width: 300.3pt; height: 142.35pt;"
 +
valign="top" width="400">
 +
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
 +
align="left"><img style="width: 395px; height: 198px;"
 +
src="https://static.igem.org/mediawiki/2010/4/44/Freiburg10_His-tag.png"
 +
alt="" align="left" hspace="12"></p>
 +
</td>
 +
</tr>
 +
<tr style="height: 22.6pt;">
 +
<td style="padding: 0cm 5.4pt; width: 300.3pt; height: 22.6pt;"
 +
valign="top" width="400">
 +
<p style="text-align: justify;">Schematic
 +
figure of His-affinity Tag insertion into the viral capsid</p>
 +
</td>
 +
</tr>
 +
</tbody>
</table>
</table>
-
 
</div>
</div>
-
 
+
<p style="text-align: justify;">The insertion of a His-Affinity Tag
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
into the exposed major surface
-
lang=EN-US style='font-size:18.0pt;line-height:200%'>&nbsp;</span></p>
+
-
 
+
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
-
lang=EN-US>The insertion of a His-Affinity Tag into the exposed major surface
+
loops of the viral vectors allows their specific affinity purification
loops of the viral vectors allows their specific affinity purification
-
employing e.g. Ni-NTA affinity chromatography. This purification method was
+
employing e.g. Ni-NTA affinity chromatography. This purification method
-
tested using the cell culture lysate of transfected AAV-293 cells that were
+
was
-
either grown in DMEM supplemented with 10% FCS or in the serum-free GIBCO®
+
tested using the cell culture lysate of transfected AAV-293 cells that
-
FreeStyle™ 293 Expression Medium (Invitrogen). The usage of serum-free media is
+
were
-
a technological modification meant to facilitate the production of pure viral
+
either grown in DMEM supplemented with 10% FCS or in the serum-free
-
vectors. Purified viral vectors are important for several applications such as
+
GIBCO®
-
animal models and biophysical characterizations. On the other hand, the elution
+
FreeStyle™ 293 Expression Medium (Invitrogen). The usage of serum-free
-
of the His-tagged viral vectors allows also enrichment of transgene viral
+
media is
-
vectors. In order to answer the question if and to what degree viral vectors
+
a technological modification meant to facilitate the production of pure
-
are transferred into the media, the cells were centrifugated, then divided into
+
viral
-
the pellet fraction and the supernatant. Physical cell lysis was performed for
+
vectors. Purified viral vectors are important for several applications
-
both fractions of the two produced batches (serum-free and FCS media) by
+
such as
-
performing four cycles of freeze and thaw.</span></p>
+
animal models and biophysical characterizations. On the other hand, the
-
 
+
elution
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
of the His-tagged viral vectors allows also enrichment of transgene
-
lang=EN-US>&nbsp;</span></p>
+
viral
-
 
+
vectors. In order to answer the question if and to what degree viral
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
+
vectors
-
style='border-collapse:collapse;border:none'>
+
are transferred into the media, the cells were centrifugated, then
-
<tr>
+
divided into
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt'>
+
the pellet fraction and the supernatant. Physical cell lysis was
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><img
+
performed for
-
  width=627 height=567 id="Bild 1"
+
both fractions of the two produced batches (serum-free and FCS media)
-
  src="!Word%20-%20for%20mergeII-Dateien/image002.gif"></p>
+
by
-
  </td>
+
performing four cycles of freeze and thaw.<br>
-
</tr>
+
&nbsp;</p>
-
<tr>
+
<table class="MsoTableGrid"
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt'>
+
style="border: medium none ; border-collapse: collapse; text-align: left; margin-left: auto; margin-right: auto;"
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
border="0" cellpadding="0" cellspacing="0">
-
  lang=EN-US>Experimental setup for the purification of His-tag presenting
+
<tbody>
-
  viral particles produced by AAV-293 cells in DMEM or the protein- and
+
<tr>
-
  animal-free Freestyle medium. Purified viral particles can be detected by
+
<td
-
  ELISA using an anti-poly-Histidine antibody or qPCR for encapsidated vector
+
style="padding: 0cm 5.4pt; vertical-align: top; width: 477.3pt;">
-
  plasmids, respectively</span></p>
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
  </td>
+
align="left"><img style="width: 627px; height: 567px;" alt=""
-
</tr>
+
id="Bild 1"
 +
src="https://static.igem.org/mediawiki/2010/0/0b/Freiburg10_His-experiment.png"></p>
 +
</td>
 +
</tr>
 +
<tr>
 +
<td style="padding: 0cm 5.4pt; width: 477.3pt;" valign="top"
 +
width="636">
 +
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
 +
align="left"><span lang="EN-US">
 +
<p style="text-align: justify;">Experimental setup for the
 +
purification of His-tag presenting viral particles produced by AAV-293
 +
cells in DMEM or the protein- and animal-free Freestyle medium.
 +
Purified viral particles can be detected by ELISA using an
 +
anti-poly-Histidine antibody or qPCR for encapsidated vector plasmids,
 +
respectively</p>
 +
</span></p>
 +
</td>
 +
</tr>
 +
</tbody>
</table>
</table>
-
 
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
align="left"><span lang="EN-US">&nbsp;</span></p>
-
lang=EN-US>&nbsp;</span></p>
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
 
+
align="left"><span lang="EN-US">
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
<h2>Material and Methods:</h2>
-
lang=EN-US>Material and Methods:</span></p>
+
</span></p>
-
 
+
<p class="MsoNormal" style="text-align: justify; text-indent: 0cm;"
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
align="left">Transfection of the AAV-293 producer
-
lang=EN-US>Transfection of the AAV-293 producer cells was performed in five 10 cm
+
cells was performed in five 10 cm
-
petri dishes with 3.6x10^6 cells, resulting in a confluency of about 70-80%
+
petri dishes with 3.6x10^6 cells, resulting in a confluency of about
-
according to the standard protocol either with cells grown in GIBCO® FreeStyle™
+
70-80%
-
293 Expression Medium (Invitrogen, protein- and animal-origin free) or in DMEM
+
according to the standard protocol either with cells grown in GIBCO®
 +
FreeStyle™
 +
293 Expression Medium (Invitrogen, protein- and animal-origin free) or
 +
in DMEM
supplemented with 10% FCS (PAA). For transfection, the composite parts
supplemented with 10% FCS (PAA). For transfection, the composite parts
-
pCMV_VP123(587-His) and RepVP123(587-KO)_p5-TATA-less were used in an 1:1 ratio
+
pCMV_VP123(587-His) and RepVP123(587-KO)_p5-TATA-less were used in an
-
together with </span><span lang=EN-US style='font-size:12.0pt;line-height:200%'>pHelper
+
1:1 ratio
-
and <span class=apple-style-span><span style='color:black'>[AAV2]-left-ITR_pCMV_betaglobin_mVenus_hGH_[AAV2]-right-ITR.</span></span></span><span
+
together with pHelper
-
lang=EN-US> Cells were spun down at 200 x g for five minutes and the samples
+
and [AAV2]-left-ITR_pCMV_betaglobin_mVenus_hGH_[AAV2]-right-ITR. Cells
-
were divided into the pellet and the supernatant fractions. Physical cell lysis
+
were spun down at 200 x g for five minutes and the
-
was performed by four cycles of freeze and thaw for all four samples. The cell
+
samples
-
lysate / supernatant fractions were incubated with 800 µl of His-Affinity Gel
+
were divided into the pellet and the supernatant fractions. Physical
-
(kindly provided by Zymo Research, USA) at 4 °C for 18 hours with 200 rpm constant
+
cell lysis
-
agitation. The beads were then collected in 5 ml gravity-flow columns and
+
was performed by four cycles of freeze and thaw for all four samples.
-
washed five times with one column volume of PBS each. The His-affinity gel was subsequently
+
The cell
-
washed with PBS, 25 mM Imidazole to remove unspecifically bound proteins.
+
lysate / supernatant fractions were incubated with 800 µl of
-
Elution was performed in an second step with PBS, 500 mM Imidazole to elute the
+
His-Affinity Gel
-
His-tagged viral vectors. The genomic titer of the purified viral vectors was
+
(kindly provided by Zymo Resear&nbsp;&nbsp;&nbsp; ch, USA) at 4 °C for
-
detected via q-PCR. In an ELISA, viral vectors were captured employing the
+
18 hours with 200
-
monoclonal antibody A20 (kindly provided by PD Dr. J. Kleinschmidt, DKFZ, Heidelberg)
+
rpm constant
 +
agitation. The beads were then collected in 5 ml gravity-flow columns
 +
and
 +
washed five times with one column volume of PBS each. The His-affinity
 +
gel was subsequently
 +
washed with PBS, 25 mM Imidazole to remove unspecifically bound
 +
proteins.
 +
Elution was performed in an second step with PBS, 500 mM Imidazole to
 +
elute the
 +
His-tagged viral vectors. The genomic titer of the purified viral
 +
vectors was
 +
detected via q-PCR. In an ELISA, viral vectors were captured employing
 +
the
 +
monoclonal antibody A20 (kindly provided by PD Dr. J. Kleinschmidt,
 +
DKFZ, Heidelberg)
that exclusively recognizes assembled AAV capsids. His-Tags present in
that exclusively recognizes assembled AAV capsids. His-Tags present in
-
assembled viral capsids were subsequently detected with an HRP-tagged secondary
+
assembled viral capsids were subsequently detected with an HRP-tagged
-
anti-His-Tag antibody (1:2000 diluted, A7058, Sigma). </span><span lang=EN-US
+
secondary
-
style='font-size:12.0pt;line-height:200%'>HRP presence was detected using the
+
anti-His-Tag antibody (1:2000 diluted, A7058, Sigma). HRP presence
-
peroxidase substrate ABTS. Generation of blue-green color (absorption at 405
+
was detected using the
-
nm) was measured in a Tecan Sunrise plate reader. Sample data were blanked with
+
peroxidase substrate ABTS. Generation of blue-green color (absorption
-
the average of the non-template controls (NTC).</span></p>
+
at 405
-
 
+
nm) was measured in a Tecan Sunrise plate reader. Sample data were
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
blanked with
-
lang=EN-US>&nbsp;</span></p>
+
the average of the non-template controls (NTC). <br>
-
 
+
</p>
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
lang=EN-US>Results and Discussion:</span></p>
+
align="left"><span lang="EN-US">
-
 
+
<h2>Results and Discussion</h2>
-
<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=229
+
</span></p>
-
style='width:171.65pt;margin-left:2.75pt;border-collapse:collapse'>
+
<p class="MsoNormal"
-
<tr style='height:15.2pt'>
+
style="margin-bottom: 0.0001pt; text-indent: 0cm; line-height: normal;"><span
-
  <td width=229 nowrap valign=bottom style='width:171.65pt;padding:0cm 3.5pt 0cm 3.5pt;
+
lang="EN-US">
-
  height:15.2pt'>
+
<p style="text-align: justify;">Presence of the His-affinity tag in
-
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-indent:
+
the viral capsid was detected and the ELISA enabled quantification of
-
  0cm;line-height:normal'><span lang=EN-US style='color:black'>&nbsp;</span></p>
+
the
-
  </td>
+
purification procedure efficiency. The absorbance measured for the
-
</tr>
+
elution
-
</table>
+
fractions of the 1/10 diluted samples sums up to 2.3 for the DMEM- and
-
 
+
0.5 for
-
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-indent:
+
the Free Style 293-grown cells, assigning the DMEM-grown cells a five
-
0cm;line-height:normal'><span lang=EN-US>Presence of the His-affinity tag in
+
times
-
the viral capsid was detected and the ELISA enabled quantification of the
+
higher production efficiency. Comparison between the cell pellet and
-
purification procedure efficiency. The absorbance measured for the elution
+
the
-
fractions of the 1/10 diluted samples sums up to 2.3 for the DMEM- and 0.5 for
+
supernatant fractions revealed that 70 - 80% of the viral particles can
-
the Free Style 293-grown cells, assigning the DMEM-grown cells a five times
+
be
-
higher production efficiency. Comparison between the cell pellet and the
+
found inside the producer cells.</p>
-
supernatant fractions revealed that 70 - 80% of the viral particles can be
+
</span></p>
-
found inside the producer cells.</span></p>
+
<p class="MsoNormal"
-
 
+
style="margin-bottom: 10pt; text-align: left; text-indent: 0cm; line-height: 115%;"
-
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-indent:
+
align="left"><span lang="EN-US">
-
0cm;line-height:normal'><span lang=EN-US>&nbsp;</span></p>
+
<p style="text-align: justify;">According to these results,
-
 
+
producer cells should be grown in complex media for <i>in vitro</i>
-
<p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
and cell
-
text-indent:0cm;line-height:115%'><span lang=EN-US>According to these results,
+
culture experiments. Use of serum-free produced viral vectors is
-
producer cells should be grown in complex media for <i>in vitro</i> and cell
+
recommended
-
culture experiments. Use of serum-free produced viral vectors is recommended
+
for mouse or other animal experiments and possible therapeutical
-
for mouse or other animal experiments and possible therapeutical applications
+
applications
where even the presence of traces amounts of fetal calf serum should be
where even the presence of traces amounts of fetal calf serum should be
avoided. Combination with different purification approaches such as gel
avoided. Combination with different purification approaches such as gel
-
filtration chromatography using i.e. Superdex 200 columns (GE Healthcare)
+
filtration chromatography using i.e. Superdex 200 columns (GE
-
enables the production of highly purified viral vectors for several different
+
Healthcare)
-
applications.<br clear=all style='page-break-before:always'>
+
enables the production of highly purified viral vectors for several
 +
different
 +
applications.</p>
 +
<br style="page-break-before: always;" clear="all">
</span></p>
</span></p>
-
 
+
<table class="MsoTableGrid"
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
+
style="border: medium none ; border-collapse: collapse; text-align: left; margin-left: auto; margin-right: auto;"
-
style='border-collapse:collapse;border:none'>
+
border="0" cellpadding="0" cellspacing="0">
-
<tr>
+
<tbody>
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt'>
+
<tr>
-
  <p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
<td style="padding: 0cm 5.4pt; width: 477.3pt;" valign="top"
-
  text-indent:0cm;line-height:115%'><img width=451 height=796
+
width="636">
-
  src="!Word%20-%20for%20mergeII-Dateien/image003.gif" align=left hspace=12></p>
+
<p class="MsoNormal"
-
  </td>
+
style="margin-bottom: 10pt; text-align: left; text-indent: 0cm; line-height: 115%;"
-
</tr>
+
align="left"><img style="width: 451px; height: 796px;" alt=""
-
<tr>
+
src="https://static.igem.org/mediawiki/2010/0/0d/Freiburg10_His-data.png"
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt'>
+
align="left" hspace="12"></p>
-
  <p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
</td>
-
  text-indent:0cm;line-height:115%'><span lang=EN-US>A: Schematic overview of
+
</tr>
-
  the sandwich ELISA for the detection of His-tagged viral particles</span></p>
+
<tr>
-
  <p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
<td style="padding: 0cm 5.4pt; width: 477.3pt;" valign="top"
-
  text-indent:0cm;line-height:115%'><span lang=EN-US>B: ELISA from viral
+
width="636">
-
  particles produced by AAV-293 cells in DMEM or Free Style medium, divided
+
<p class="MsoNormal"
-
  into cell pellet and cell culture supernatant samples. The particles were
+
style="margin-bottom: 10pt; text-align: left; text-indent: 0cm; line-height: 115%;"
-
  purified using Ni-NTA affinity chromatography with Imidazole in PBS as washing
+
align="left"><span lang="EN-US">A: Schematic overview of the sandwich
-
  and elution agent</span></p>
+
ELISA for the detection of His-tagged viral particles</span></p>
-
  <p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
<p class="MsoNormal"
-
  text-indent:0cm;line-height:115%'><span lang=EN-US>C: Absorption measurements
+
style="margin-bottom: 10pt; text-align: left; text-indent: 0cm; line-height: 115%;"
-
  from plate shown in B. Undiluted Äkta fractions converted ABTS peroxidase
+
align="left"><span lang="EN-US">B: ELISA from viral particles produced
-
  substrate at 405 nm</span></p>
+
by AAV-293 cells in DMEM or Free Style medium, divided into cell pellet
-
  <p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
and cell culture supernatant samples. The particles were purified using
-
  text-indent:0cm;line-height:115%'><span lang=EN-US>D: As C, whereas Äkta
+
Ni-NTA affinity chromatography with Imidazole in PBS as washing and
-
  fractions were 10-fold diluted</span></p>
+
elution agent</span></p>
-
  </td>
+
<p class="MsoNormal"
-
</tr>
+
style="margin-bottom: 10pt; text-align: left; text-indent: 0cm; line-height: 115%;"
 +
align="left"><span lang="EN-US">C: Absorption measurements from plate
 +
shown in B. Undiluted Äkta fractions converted ABTS peroxidase
 +
substrate at 405 nm</span></p>
 +
<p class="MsoNormal"
 +
style="margin-bottom: 10pt; text-align: left; text-indent: 0cm; line-height: 115%;"
 +
align="left"><span lang="EN-US">D: As C, whereas Äkta fractions were
 +
10-fold diluted</span></p>
 +
</td>
 +
</tr>
 +
</tbody>
</table>
</table>
-
 
+
<br>
-
<span lang=EN-US style='font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"'><br
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
clear=all style='page-break-before:always'>
+
align="left">
-
</span>
+
<h1>Biotinylation Acceptor
-
 
+
Peptide (BAP)</h1>
-
<p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
</p>
-
text-indent:0cm;line-height:115%'><span lang=EN-US>&nbsp;</span></p>
+
<div align="center">
-
 
+
<table class="MsoTableGrid"
-
<p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
style="border: medium none ; border-collapse: collapse;" border="0"
-
text-indent:0cm;line-height:115%'><span lang=EN-US>&nbsp;</span></p>
+
cellpadding="0" cellspacing="0">
-
 
+
<tbody>
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
<tr style="height: 187.45pt;">
-
lang=EN-US style='font-size:20.0pt;line-height:200%'>Biotinylation Acceptor
+
<td style="padding: 0cm 5.4pt; width: 327.6pt; height: 187.45pt;"
-
Peptide (BAP)</span></p>
+
valign="top" width="437">
-
 
+
<p class="MsoNormal" style="text-indent: 0cm;"><img
-
<div align=center>
+
style="width: 419px; height: 244px;"
-
 
+
src="https://static.igem.org/mediawiki/2010/e/ea/Freiburg10_BAP-tag.png"
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
+
alt="http://partsregistry.org/wiki/images/a/a9/Freiburg10_ViralBrick_motif_BAP.png"
-
style='border-collapse:collapse;border:none'>
+
align="left" hspace="12"></p>
-
<tr style='height:187.45pt'>
+
</td>
-
  <td width=437 valign=top style='width:327.6pt;padding:0cm 5.4pt 0cm 5.4pt;
+
</tr>
-
  height:187.45pt'>
+
<tr style="height: 39.75pt;">
-
  <p class=MsoNormal style='text-indent:0cm'><img width=419 height=244
+
<td style="padding: 0cm 5.4pt; width: 327.6pt; height: 39.75pt;"
-
  src="!Word%20-%20for%20mergeII-Dateien/image004.gif" align=left hspace=12
+
valign="top" width="437">
-
  alt="http://partsregistry.org/wiki/images/a/a9/Freiburg10_ViralBrick_motif_BAP.png"></p>
+
<p class="MsoNormal" style="text-indent: 0cm;"><span
-
  </td>
+
style="line-height: 100%;" lang="EN-US">
-
</tr>
+
<p style="text-align: justify;">Schematic overview of BAP
-
<tr style='height:39.75pt'>
+
insertion into AAV-2 viral capsids, followed by biotinylation and
-
  <td width=437 valign=top style='width:327.6pt;padding:0cm 5.4pt 0cm 5.4pt;
+
binding of streptavidin-coupled molecules</p>
-
  height:39.75pt'>
+
</span></p>
-
  <p class=MsoNormal style='text-indent:0cm'><span lang=EN-US style='line-height:
+
</td>
-
  200%'>Schematic overview of BAP insertion into AAV-2 viral capsids, followed
+
</tr>
-
  by biotinylation and binding of streptavidin-coupled molecules</span></p>
+
</tbody>
-
  </td>
+
-
</tr>
+
</table>
</table>
-
 
</div>
</div>
-
 
+
<p style="text-align: justify;">The
-
<p class=MsoNormal style='text-indent:0cm'><span lang=EN-US>The BAP
+
BAP
-
(Biotinylation Acceptor Peptide) included in the Virus Construction Kit is a 15
+
(Biotinylation Acceptor Peptide) included in the Virus Construction Kit
-
amino acid peptide identified by Schatz et al. (1993) in a library screening
+
is a 15
-
approach and published under the number #85. This peptide with the sequence
+
amino acid peptide identified by Schatz et al. (1993) in a library
-
GLNDIFEAQKIEWHE contains a central lysine residue that can be specifically
+
screening
-
biotinylated by the prokaryotic holoenzyme biotin synthetase, encoded by the
+
approach and published under the number #85. This peptide with the
-
BirA gene of <i>E. coli</i>. Specific biotinylation of this peptide sequence
+
sequence
-
can be performed in vivo by cotransfecting a plasmid with the BirA gene as
+
GLNDIFEAQKIEWHE contains a central lysine residue that can be
-
described for the AAV by Arnold et al. (2006) or by an in vitro coupling
+
specifically
-
approach using the purified Escherichia coli enzyme biotin ligase (BirA).&nbsp;</span></p>
+
biotinylated by the prokaryotic holoenzyme biotin synthetase, encoded
-
 
+
by the
-
<p class=MsoNormal style='text-indent:0cm'><span lang=EN-US>Biotin molecules
+
BirA gene of <i>E. coli</i>. Specific biotinylation of this peptide
-
specifically coupled to the viral loops can either be used to attach Streptavidin-coupled
+
sequence
-
molecules to the viral capsid or to chemically couple molecules with a reactive
+
can be performed in vivo by cotransfecting a plasmid with the BirA gene
-
group to biotin. Consequently, the inserted motif can enable the visualization
+
as
 +
described for the AAV by Arnold et al. (2006) or by an in vitro
 +
coupling
 +
approach using the purified Escherichia coli enzyme biotin ligase
 +
(BirA). <span lang="EN-US"><br>
 +
</span></p>
 +
<p class="MsoNormal" style="text-indent: 0cm;"><span lang="EN-US">
 +
<p class="MsoNormal" style="text-indent: 0cm;"><span lang="EN-US">
 +
<p style="text-align: justify;">Biotin
 +
molecules
 +
specifically coupled to the viral loops can either be used to attach
 +
Streptavidin-coupled
 +
molecules to the viral capsid or to chemically couple molecules with a
 +
reactive
 +
group to biotin. Consequently, the inserted motif can enable the
 +
visualization
of single virus particles by coupling fluorophores to the virus capsid
of single virus particles by coupling fluorophores to the virus capsid
empowering further uses of the Virus Construction Kit in fundamental
empowering further uses of the Virus Construction Kit in fundamental
virological research. In addition, targeting molecules such as
virological research. In addition, targeting molecules such as
Streptavidin-coupled affinity molecules (i.e. Antibodies, Nanobodies or
Streptavidin-coupled affinity molecules (i.e. Antibodies, Nanobodies or
-
Affibodies) can be coupled for manifold targeting approaches.</span></p>
+
Affibodies) can be coupled for manifold targeting approaches.</p>
-
 
+
</span></p>
-
<p class=MsoNormal style='text-indent:0cm'><span lang=EN-US>&nbsp;</span></p>
+
</span></p>
-
 
+
<p class="MsoNormal" style="text-indent: 0cm;"><span lang="EN-US">
-
<span lang=EN-US style='font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"'><br
+
<h2>Materials
-
clear=all style='page-break-before:always'>
+
and Methods:<span lang="EN-US">&nbsp;</span></h2>
-
</span>
+
</span></p>
-
 
+
<p class="MsoNormal" style="text-indent: 0cm;"><span lang="EN-US">
-
<p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
<p style="text-align: justify;">Transfection
-
text-indent:0cm;line-height:115%'><span lang=EN-US>&nbsp;</span></p>
+
of the
-
 
+
AAV-293 producer cells was performed in five 10 cm petri dishes with
-
<p class=MsoNormal style='text-indent:0cm'><span lang=EN-US>Materials and Methods:</span></p>
+
3.4x10^6
-
 
+
cells (grown in DMEM supplemented with 10% FCS) resulting in a
-
<p class=MsoNormal style='text-indent:0cm'><span lang=EN-US>&nbsp;</span></p>
+
confluence of
-
 
+
70-80% according to the standard protocol. Producer cells were
-
<p class=MsoNormal style='text-indent:0cm'><span lang=EN-US>Transfection of the
+
harvested and
-
AAV-293 producer cells was performed in five 10 cm petri dishes with 3.4x10^6
+
together with the culture supernatant subjected to four cycles of
-
cells (grown in DMEM supplemented with 10% FCS) resulting in a confluence of
+
freeze and
-
70-80% according to the standard protocol. Producer cells were harvested and
+
thaw cell lysis. The cell lysate was centrifuged at 4000 rpm for 15
-
together with the culture supernatant subjected to four cycles of freeze and
+
minutes and
-
thaw cell lysis. The cell lysate was centrifuged at 4000 rpm for 15 minutes and
+
concentrated in a VivaSpin VS2002 column with 10 kDa molecular weight
-
concentrated in a VivaSpin VS2002 column with 10 kDa molecular weight cut-off to
+
cut-off to
-
yield two milliliters. Genomic DNA attached to the virus particles was degraded
+
yield two milliliters. Genomic DNA attached to the virus particles was
-
using 250 units of Benzonase (EC 3.1.30.2, Sigma-Aldrich) at 37 °C for one
+
degraded
-
hour. The concentrated cell lysate was washed three times with 4 ml 20 mM
+
using 250 units of Benzonase (EC 3.1.30.2, Sigma-Aldrich) at 37 °C for
-
bis-Tris buffer pH 6.0, 100 mM NaCl. From this concentrated sample, 500 µl were
+
one
-
loaded on the ÄKTA purifier (GE Healthcare) equipped with a Superdex 200 gel
+
hour. The concentrated cell lysate was washed three times with 4 ml 20
-
filtration column (GE Healthcare). This purification is also described by <span
+
mM
-
class=apple-converted-space><span style='color:black'>Smith et al. (2003). Fractions
+
bis-Tris buffer pH 6.0, 100 mM NaCl. From this concentrated sample, 500
-
around the void volume giving a UV absorbance peak were pooled and applied to a
+
µl were
-
Amicon Ultra column (Millipore, size limit 100 kDa, 2 ml loading volume) and
+
loaded on the ÄKTA purifier (GE Healthcare) equipped with a Superdex
-
concentrated to 500 µl. This purified virus sample was washed four times with 10
+
200 gel
-
mM Tris-buffer pH 8.0 buffer which is recommended for the BirA biotin ligase
+
filtration column (GE Healthcare). This purification is also described
-
that was kindly provided by Avidity LCC (Colorado, USA).</span></span></span></p>
+
by <span class="apple-converted-space"><span style="color: black;">Smith
-
 
+
et al. (2003). Fractions
-
<p class=MsoNormal style='text-indent:0cm'><span class=apple-converted-space><span
+
around the void volume giving a UV absorbance peak were pooled and
-
lang=EN-US style='color:black'>The BAP-containing viral vector sample (500 µl)
+
applied to a
-
was mixed according to the manufacturer protocol with each 72 µl Biomix A,
+
Amicon Ultra column (Millipore, size limit 100 kDa, 2 ml loading
 +
volume) and
 +
concentrated to 500 µl. This purified virus sample was washed four
 +
times with 10
 +
mM Tris-buffer pH 8.0 buffer which is recommended for the BirA biotin
 +
ligase
 +
that was kindly provided by Avidity LCC (Colorado, USA).</span></span></p>
 +
</span></p>
 +
<p class="MsoNormal" style="text-indent: 0cm;"><span
 +
style="color: black;" lang="EN-US">
 +
<p style="text-align: justify;">The
 +
BAP-containing viral vector sample (500 µl)
 +
was mixed according to the manufacturer protocol with each 72 µl Biomix
 +
A,
Biomix B and Biotin. To reach maximal biotinylation, a volume of 5 µl
Biomix B and Biotin. To reach maximal biotinylation, a volume of 5 µl
-
containing 25000 units of the biotin ligase BirA was added to the reaction
+
containing 25000 units of the biotin ligase BirA was added to the
-
mixture and incubated for 6 h at 30 °C. In order to remove unbound biotin, the
+
reaction
-
biotinylated viral vectors were washed five times with 10 mM Tris buffer pH 8.0.
+
mixture and incubated for 6 h at 30 °C. In order to remove unbound
-
</span></span></p>
+
biotin, the
-
 
+
biotinylated viral vectors were washed five times with 10 mM Tris
-
<p class=MsoNormal style='text-indent:0cm'><span class=apple-converted-space><span
+
buffer pH 8.0.
-
lang=EN-US style='color:black'>&nbsp;</span></span></p>
+
</p>
-
 
+
</span></p>
-
<p class=MsoNormal style='text-indent:0cm'><span class=apple-converted-space><span
+
<p class="MsoNormal" style="text-indent: 0cm;"><span
-
lang=EN-US style='color:black'>Biotinylation was verified with an ELISA as
+
style="color: black;" lang="EN-US">
-
depicted in figure A. For the detection of successfully biotinylated viral
+
<p style="text-align: justify;">Biotinylation
-
vectors, MaxiSorp 96-well plates (Nunc) were coated with 200 ng monoclonal A20
+
was verified with an ELISA as
-
antibody per well for eight hours at 4°C, and blocked over night with PBST +
+
depicted in figure A. For the detection of successfully biotinylated
-
0.5 % BSA. This plate was incubated for 1 h at room temperature with 100 µl of
+
viral
 +
vectors, MaxiSorp 96-well plates (Nunc) were coated with 200 ng
 +
monoclonal A20
 +
antibody per well for eight hours at 4°C, and blocked over night with
 +
PBST +
 +
0.5 % BSA. This plate was incubated for 1 h at room temperature with
 +
100 µl of
serial diluted viral vectors. After washing the plates three times, the
serial diluted viral vectors. After washing the plates three times, the
-
recommended amount of Streptavidin-HRP conjugate (Sigma-Aldrich) was added to
+
recommended amount of Streptavidin-HRP conjugate (Sigma-Aldrich) was
-
each well for 1 h at room temperature. Again, the plates were washed three
+
added to
-
times followed by detection of absorbance caused by converted ABTS substrate at
+
each well for 1 h at room temperature. Again, the plates were washed
-
405 nm. Additionally, the genomic AAV-2 titer was determined by qPCR.</span></span></p>
+
three
-
 
+
times followed by detection of absorbance caused by converted ABTS
-
<span class=apple-converted-space><span lang=EN-US style='font-size:11.0pt;
+
substrate at
-
line-height:115%;font-family:"Calibri","sans-serif";color:black'><br clear=all
+
405 nm. Additionally, the genomic AAV-2 titer was determined by qPCR.</p>
-
style='page-break-before:always'>
+
</span></p>
-
</span></span>
+
<span class="apple-converted-space"><span
-
 
+
style="font-size: 11pt; line-height: 115%; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;; color: black;"
-
<p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
lang="EN-US"></span></span><span class="apple-converted-space"><span
-
text-indent:0cm;line-height:115%'><span class=apple-converted-space><span
+
style="color: black;" lang="EN-US">&nbsp;</span></span>
-
lang=EN-US style='color:black'>&nbsp;</span></span></p>
+
<table class="MsoTableGrid"
-
 
+
style="border: medium none ; border-collapse: collapse; text-align: left; margin-left: auto; margin-right: auto;"
-
<p class=MsoNormal style='text-indent:0cm'><span class=apple-converted-space><span
+
border="0" cellpadding="0" cellspacing="0">
-
lang=EN-US style='color:black'>&nbsp;</span></span></p>
+
<tbody>
-
 
+
<tr>
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
+
<td style="padding: 0cm 5.4pt; width: 477.3pt;" valign="top"
-
style='border-collapse:collapse;border:none'>
+
width="636">
-
<tr>
+
<p class="MsoNormal" style="text-indent: 0cm;"><img
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt'>
+
style="width: 587px; height: 539px;" alt=""
-
  <p class=MsoNormal style='text-indent:0cm'><img width=587 height=539
+
src="https://static.igem.org/mediawiki/2010/2/2c/Freiburg10_BAP-data.png"
-
  src="!Word%20-%20for%20mergeII-Dateien/image005.gif" align=left hspace=12></p>
+
align="left" hspace="12"></p>
-
  </td>
+
</td>
-
</tr>
+
</tr>
-
<tr>
+
<tr>
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt'>
+
<td style="padding: 0cm 5.4pt; width: 477.3pt;" valign="top"
-
  <p class=MsoNormal style='text-indent:0cm'><span class=apple-converted-space><span
+
width="636">
-
  lang=EN-US style='color:black'>A: Schematic overview of the detection of
+
<p class="MsoNormal" style="text-indent: 0cm;"><span
-
  BAP-presenting viral particles immobilized by A20 capture antibodies.
+
class="apple-converted-space"><span style="color: black;" lang="EN-US">A:
-
  Biotinylated capsids can be detected by streptavidin-coupled HRP</span></span></p>
+
Schematic overview of the detection of BAP-presenting viral particles
-
  <p class=MsoNormal style='text-indent:0cm'><span class=apple-converted-space><span
+
immobilized by A20 capture antibodies. Biotinylated capsids can be
-
  lang=EN-US style='color:black'>B: ELISA AAV-2 particles carrying a BAP
+
detected by streptavidin-coupled HRP</span></span></p>
-
  insertion in loop 587 which can be specifically biotinylated in vitro</span></span></p>
+
<p class="MsoNormal" style="text-indent: 0cm;"><span
-
  </td>
+
class="apple-converted-space"><span style="color: black;" lang="EN-US">B:
-
</tr>
+
ELISA AAV-2 particles carrying a BAP insertion in loop 587 which can be
 +
specifically biotinylated in vitro</span></span></p>
 +
</td>
 +
</tr>
 +
</tbody>
</table>
</table>
-
 
+
<span class="apple-converted-space"><span
-
<p class=MsoNormal style='text-indent:0cm'><span class=apple-converted-space><span
+
style="font-size: 11pt; line-height: 115%; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;; color: black;"
-
lang=EN-US style='color:black'>&nbsp;</span></span></p>
+
lang="EN-US">
-
 
+
-
<span class=apple-converted-space><span lang=EN-US style='font-size:11.0pt;
+
-
line-height:115%;font-family:"Calibri","sans-serif";color:black'><br clear=all
+
-
style='page-break-before:always'>
+
</span></span>
</span></span>
-
 
+
<p class="MsoNormal" style="text-indent: 0cm;"><span
-
<p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
class="apple-converted-space"><span style="color: black;" lang="EN-US">
-
text-indent:0cm;line-height:115%'><span class=apple-converted-space><span
+
<h2>Results
-
lang=EN-US style='color:black'>&nbsp;</span></span></p>
+
and Discussion:</h2>
-
 
+
</span></span><span lang="EN-US"> </span></p>
-
<p class=MsoNormal style='text-indent:0cm'><span class=apple-converted-space><span
+
<p class="MsoNormal" style="text-indent: 0cm;"><span lang="EN-US">
-
lang=EN-US style='color:black'>Results and Discussion:</span></span><span
+
<p style="text-align: justify;">As
-
lang=EN-US> </span></p>
+
can be seen in
-
 
+
figure B, biotinylation of assembled AAV particles was achieved with
-
<p class=MsoNormal style='text-indent:0cm'><span lang=EN-US>As can be seen in
+
the
-
figure B, biotinylation of assembled AAV particles was achieved with the
+
dilution series ranging from 2- to 128-fold. Correlating this assay
-
dilution series ranging from 2- to 128-fold. Correlating this assay with the
+
with the
-
qPCR experiment for the detection of encapsidated vector plasmid (genomic titer
+
qPCR experiment for the detection of encapsidated vector plasmid
 +
(genomic titer
using CMV-promoter primers) yields a value of 4.70E+07 DNase-resistant
using CMV-promoter primers) yields a value of 4.70E+07 DNase-resistant
-
particles (DRP). Consequently, the presence of approximately 3.6x10^5 biotinylated
+
particles (DRP). Consequently, the presence of approximately 3.6x10^5
-
DRPs can be detected using the described ELISA. Compared to the virus particle
+
biotinylated
-
detection ELISA emploing A20 as capture- and detection antibody, the detection
+
DRPs can be detected using the described ELISA. Compared to the virus
-
limit of the biotinylated viral capsids is about 10fold more sensitive. This
+
particle
-
may be explained by the higher affinity of strepavidin towards biotin relative
+
detection ELISA emploing A20 as capture- and detection antibody, the
-
to the A20 antibody affinity or multiple biotinylation of a single virus
+
detection
-
particle.</span></p>
+
limit of the biotinylated viral capsids is about 10fold more sensitive.
-
 
+
This
-
<span lang=EN-US style='font-size:20.0pt;line-height:115%;font-family:"Calibri","sans-serif"'><br
+
may be explained by the higher affinity of strepavidin towards biotin
-
clear=all style='page-break-before:always'>
+
relative
-
</span>
+
to the A20 antibody affinity or multiple biotinylation of a single
-
 
+
virus
-
<p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
particle.</p>
-
text-indent:0cm;line-height:115%'><span lang=EN-US style='font-size:20.0pt;
+
<p style="text-align: justify;"><br>
-
line-height:115%'>&nbsp;</span></p>
+
</p>
-
 
+
</span></p>
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
<span
-
lang=EN-US style='font-size:20.0pt;line-height:200%'>Miniaturized antibody
+
style="font-size: 20pt; line-height: 115%; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;"
-
binding domain (Z34C)</span></p>
+
lang="EN-US"></span><span style="font-size: 20pt; line-height: 115%;"
-
 
+
lang="EN-US"></span>
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
style='border-collapse:collapse;border:none'>
+
align="left">
-
<tr style='height:184.6pt'>
+
<h1>Miniaturized antibody
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt;
+
binding domain (Z34C)</h1>
-
  height:184.6pt'>
+
</p>
-
  <p class=MsoNormal style='text-indent:0cm'><img width=451 height=225
+
<table class="MsoTableGrid"
-
  src="!Word%20-%20for%20mergeII-Dateien/image006.gif" align=left hspace=12
+
style="border: medium none ; border-collapse: collapse;" border="0"
-
  alt="http://partsregistry.org/wiki/images/9/98/Freiburg10_ViralBrick_motif_Z34C.png"></p>
+
cellpadding="0" cellspacing="0">
-
  </td>
+
<tbody>
-
</tr>
+
<tr style="height: 184.6pt;">
-
<tr style='height:23.7pt'>
+
<td style="padding: 0cm 5.4pt; width: 477.3pt; height: 184.6pt;"
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt;
+
valign="top" width="636">
-
  height:23.7pt'>
+
<p class="MsoNormal" style="text-indent: 0cm;"><img
-
  <p class=MsoNormal style='text-indent:0cm'><span lang=EN-US style='line-height:
+
style="width: 451px; height: 225px;"
-
  200%'>Schematic overview of Z34C insertion into AAV-2 viral capsids enabling
+
src="https://static.igem.org/mediawiki/2010/6/63/Freiburg10_Z34C-tag.png"
-
  antibody arming for therapy</span></p>
+
alt="" align="left" hspace="12"></p>
-
  </td>
+
</td>
-
</tr>
+
</tr>
 +
<tr style="height: 23.7pt;">
 +
<td style="padding: 0cm 5.4pt; width: 477.3pt; height: 23.7pt;"
 +
valign="top" width="636">
 +
<p style="text-align: justify;">Schematic overview of Z34C
 +
insertion into AAV-2 viral capsids enabling antibody arming for therapy</p>
 +
</td>
 +
</tr>
 +
</tbody>
</table>
</table>
-
 
+
<p class="MsoNormal" style="text-indent: 0cm;"><span lang="EN-US">
-
<p class=MsoNormal style='text-indent:0cm'><span lang=EN-US>The idea of this
+
<p style="text-align: justify;">The
-
targeting approach is to utilize a minimized fragment of the </span><a
+
idea of this
-
href="http://www.ncbi.nlm.nih.gov/protein/153106"><span lang=EN-US
+
targeting approach is to utilize a minimized fragment of the <a
-
style='color:windowtext;text-decoration:none'>Staphylococcal Protein A</span></a><span
+
href="http://www.ncbi.nlm.nih.gov/protein/153106"><span
-
lang=EN-US>&nbsp;that was first described in Staphylococcus aureus. These
+
style="color: windowtext; text-decoration: none;" lang="EN-US">Staphylococcal
-
gram-positive bacteria have evolved the 508 amino acid long protein A that has
+
Protein A</span></a><span lang="EN-US">&nbsp;that was first described
-
a high affinity for the Fc-domain of antibodies to protect itself from the
+
in Staphylococcus aureus. These
-
immune system. Binding to the constant region of the antibodies is accomplished
+
gram-positive bacteria have evolved the 508 amino acid long protein A
 +
that has
 +
a high affinity for the Fc-domain of antibodies to protect itself from
 +
the
 +
immune system. Binding to the constant region of the antibodies is
 +
accomplished
by the&nbsp;</span><a href="http://www.ncbi.nlm.nih.gov/protein/1Q2NA"><span
by the&nbsp;</span><a href="http://www.ncbi.nlm.nih.gov/protein/1Q2NA"><span
-
lang=EN-US style='color:windowtext;text-decoration:none'>Z-Domain</span></a><span
+
style="color: windowtext; text-decoration: none;" lang="EN-US">Z-Domain</span></a><span
-
lang=EN-US>&nbsp;of Protein A that is 58-59 amino acids long, has alone a high
+
lang="EN-US">&nbsp;of Protein A that is 58-59 amino acids long, has
-
affinity (Kd= 14,9 nM) for the antibodies and a three-helix bundle structure.
+
alone a high
 +
affinity (Kd= 14,9 nM) for the antibodies and a three-helix bundle
 +
structure.
In&nbsp;</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/8650153"><span
In&nbsp;</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/8650153"><span
-
lang=EN-US style='color:windowtext;text-decoration:none'>[Braisted &amp; Wells;
+
style="color: windowtext; text-decoration: none;" lang="EN-US">[Braisted
-
1996]</span></a><span lang=EN-US>&nbsp;the authors reduced the secundary
+
&amp; Wells;
-
structure to an two-helix bundle. This size reduction has lead to an drastic
+
1996]</span></a><span lang="EN-US">&nbsp;the authors reduced the
-
reduction of the affinity for IgG (&gt;10^5 fold) which could be recovered by
+
secundary
-
13 amino acid exchanges resulting in a 38 amino acid long peptide with an
+
structure to an two-helix bundle. This size reduction has lead to an
 +
drastic
 +
reduction of the affinity for IgG (&gt;10^5 fold) which could be
 +
recovered by
 +
13 amino acid exchanges resulting in a 38 amino acid long peptide with
 +
an
satisfying affinity for IgG (Kd = 185 nM) termed&nbsp;</span><a
satisfying affinity for IgG (Kd = 185 nM) termed&nbsp;</span><a
-
href="http://www.ncbi.nlm.nih.gov/protein/1ZDAA"><span lang=EN-US
+
href="http://www.ncbi.nlm.nih.gov/protein/1ZDAA"><span
-
style='color:windowtext;text-decoration:none'>Z38</span></a><span lang=EN-US>.
+
style="color: windowtext; text-decoration: none;" lang="EN-US">Z38</span></a><span
 +
lang="EN-US">.
This binding domain was subsequently improved in&nbsp;</span><a
This binding domain was subsequently improved in&nbsp;</span><a
-
href="http://www.ncbi.nlm.nih.gov/pubmed/9294166"><span lang=EN-US
+
href="http://www.ncbi.nlm.nih.gov/pubmed/9294166"><span
-
style='color:windowtext;text-decoration:none'>[Starovasnik et al.; 1997]</span></a><span
+
style="color: windowtext; text-decoration: none;" lang="EN-US">[Starovasnik
-
lang=EN-US>&nbsp;by the insertion of a disulfide bridge connecting the ends of
+
et al.; 1997]</span></a><span lang="EN-US">&nbsp;by the insertion of a
 +
disulfide bridge connecting the ends of
the helices leading to the binding domain&nbsp;</span><a
the helices leading to the binding domain&nbsp;</span><a
-
href="http://www.ncbi.nlm.nih.gov/protein/1ZDCA"><span lang=EN-US
+
href="http://www.ncbi.nlm.nih.gov/protein/1ZDCA"><span
-
style='color:windowtext;text-decoration:none'>Z34C</span></a><span lang=EN-US>&nbsp;which
+
style="color: windowtext; text-decoration: none;" lang="EN-US">Z34C</span></a><span
 +
lang="EN-US">&nbsp;which
shows an increased affinity for IgG (Kd = 20 nM).</span></p>
shows an increased affinity for IgG (Kd = 20 nM).</span></p>
-
 
+
</span></p>
-
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;line-height:200%;
+
<span
-
font-family:"Arial","sans-serif";color:black'>&nbsp;</span></p>
+
style="font-size: 10pt; line-height: 200%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black;"
-
 
+
lang="EN-US">&nbsp;</span>
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
+
<table class="MsoTableGrid"
-
style='border-collapse:collapse;border:none'>
+
style="border: medium none ; border-collapse: collapse; text-align: left; margin-left: auto; margin-right: auto;"
-
<tr>
+
border="0" cellpadding="0" cellspacing="0">
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt'>
+
<tbody>
-
  <p class=MsoNormal style='text-indent:0cm'><span style='font-size:10.0pt;
+
<tr>
-
  line-height:200%;font-family:"Arial","sans-serif";color:black'><img border=0
+
<td
-
  width=524 height=309 id="Grafik 30"
+
style="padding: 0cm 5.4pt; vertical-align: top; width: 477.3pt;">
-
  src="!Word%20-%20for%20mergeII-Dateien/image007.jpg"
+
<p class="MsoNormal" style="text-indent: 0cm;"><span
-
  alt="https://static.igem.org/mediawiki/2010/e/e9/Freiburg10_Evolution_of_Z34C.png"></span></p>
+
style="font-size: 10pt; line-height: 200%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black;"><img
-
  </td>
+
style="border: 0px solid ; width: 524px; height: 309px;" id="Grafik 30"
-
</tr>
+
src="https://static.igem.org/mediawiki/2010/c/cd/Freiburg10_Z34C-history.png"
-
<tr>
+
alt=""></span></p>
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt'>
+
</td>
-
  <p class=MsoNormal style='text-indent:0cm'><span lang=EN-US style='font-size:
+
</tr>
-
  10.0pt;line-height:200%;font-family:"Arial","sans-serif";color:black'>Development
+
<tr>
-
  of the Z34C motif, a miniaturized antibody binding motif</span></p>
+
<td style="padding: 0cm 5.4pt; width: 477.3pt;" valign="top"
-
  </td>
+
width="636">
-
</tr>
+
<p class="MsoNormal" style="text-indent: 0cm;"><span
 +
style="font-size: 10pt; line-height: 200%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black;"
 +
lang="EN-US">Development of the Z34C motif, a miniaturized antibody
 +
binding motif</span></p>
 +
</td>
 +
</tr>
 +
</tbody>
</table>
</table>
-
 
+
<span
-
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;line-height:200%;
+
style="font-size: 10pt; line-height: 200%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black;"
-
font-family:"Arial","sans-serif";color:black'><br>
+
lang="EN-US"><br>
-
</span><span lang=EN-US>This engineered antibody binding domain of 34 amino
+
</span><span lang="EN-US">
-
acids was then inserted into capsids of different viral vectors amongst others
+
<p style="text-align: justify;">This engineered antibody binding domain
-
also the AAV. In&nbsp;</span><a
+
of 34
-
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC155067"><span lang=EN-US
+
amino
-
style='color:windowtext;text-decoration:none'>[Ried et al.; 2002]</span></a><span
+
acids was then inserted into capsids of different viral vectors amongst
-
lang=EN-US>&nbsp;the&nbsp;</span><a
+
others
-
href="http://www.ncbi.nlm.nih.gov/protein/1ZDCA"><span lang=EN-US
+
also the AAV. In <a
-
style='color:windowtext;text-decoration:none'>Z34C</span></a><span lang=EN-US>&nbsp;domain
+
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC155067"><span
-
was inserted at position 587 into the capsid of the AAV resulting in viral
+
style="color: windowtext; text-decoration: none;" lang="EN-US">[Ried
 +
et al.; 2002]</span></a><span lang="EN-US">&nbsp;the&nbsp;</span><a
 +
href="http://www.ncbi.nlm.nih.gov/protein/1ZDCA"><span
 +
style="color: windowtext; text-decoration: none;" lang="EN-US">Z34C</span></a><span
 +
lang="EN-US">&nbsp;domain
 +
was inserted at position 587 into the capsid of the AAV resulting in
 +
viral
vector that can be targeted to different target cells without genetic
vector that can be targeted to different target cells without genetic
engineering. This targeting approach was then improved in&nbsp;</span><a
engineering. This targeting approach was then improved in&nbsp;</span><a
-
href="http://www.ncbi.nlm.nih.gov/pubmed/15922956"><span lang=EN-US
+
href="http://www.ncbi.nlm.nih.gov/pubmed/15922956"><span
-
style='color:windowtext;text-decoration:none'>[Gigout et al.; 2005]</span></a><span
+
style="color: windowtext; text-decoration: none;" lang="EN-US">[Gigout
-
lang=EN-US>&nbsp;by the creation of mosaic vectors that contain only ~25% of
+
et al.; 2005]</span></a>&nbsp;by the creation of
-
recombinant VP-Proteins what resulted in 4 to 5 orders of magnitude more
+
mosaic vectors that contain only ~25% of
-
infectiosity compared to all-mutant viruses.</span></p>
+
recombinant VP-Proteins what resulted in 4 to 5 orders of magnitude
-
 
+
more
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
infectiosity compared to all-mutant viruses</p>
-
lang=EN-US style='font-size:12.0pt;line-height:200%'>&nbsp;</span></p>
+
</span><span style="font-size: 12pt; line-height: 200%;" lang="EN-US"></span>
-
 
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
align="left">
-
lang=EN-US style='font-size:14.0pt;line-height:200%'>Material and Methods:</span></p>
+
<h2>Material and Methods:</h2>
-
 
+
</p>
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
<p class="MsoNormal" style="text-align: justify; text-indent: 0cm;"
-
lang=EN-US style='font-size:12.0pt;line-height:200%'>Transfection of the
+
align="left">Transfection of the
-
AAV-293 producer cells was performed for three different loop insertions of
+
AAV-293 producer cells was performed for three different loop
-
Z34C in each three 10 cm petri dishes with 3.4x10^6 cells resulting in a
+
insertions of
-
confluence of about 70-80%. For the transfection, either the composite parts pCMV_VP123(453-Z34C),
+
Z34C in each three 10 cm petri dishes with 3.4x10^6 cells resulting in
-
pCMV_VP123(587KO- Z34C) or pCMV_VP123(587Ko- Z34C-Spacer) were cotransfected
+
a
-
with pHelper, <span class=apple-style-span><span style='color:black'>[AAV2]-left-ITR_pCMV_betaglobin_mVenus_hGH_[AAV2]-right-ITR
+
confluence of about 70-80%. For the transfection, either the composite
-
and RepVP</span></span>123(587KO). The producer cells were harvested with the
+
parts pCMV_VP123(453-Z34C),
-
culture supernatant and subjected to four cycles of freeze and thaw cell lysis.
+
pCMV_VP123(587KO- Z34C) or pCMV_VP123(587Ko- Z34C-Spacer) were
-
The cell lysate was centrifuged at 4000 rpm for 15 minutes and concentrated in
+
cotransfected
-
a VivaSpin VS2002 (Sartorius Stedem) with a 10 kDa molecular weight cut-off to
+
with pHelper,
-
two milliliters and washed three to five times with 20 mM Bis-Tris buffer, pH 6.
+
[AAV2]-left-ITR_pCMV_betaglobin_mVenus_hGH_[AAV2]-right-ITR
-
The cell lysates were incubated with 250 units of Benzonase (Sigma-Aldrich) to
+
and RepVP123(587KO). The producer cells were harvested
-
remove contaminant genomic DNA and loaded on an ÄKTA purifier (GE Healthcare) equipped
+
with the
-
with a Superdex 200 gel filtration column (GE Healthcare). Fractions (500 µl)
+
culture supernatant and subjected to four cycles of freeze and thaw
-
around the void volume containing viral particles were collected and used in a
+
cell lysis.
-
sandwich ELISA. 96 well plates were coated with 200 ng Cetuximab (Imclone/Merck/Bristol-Myers
+
The cell lysate was centrifuged at 4000 rpm for 15 minutes and
-
Squibb). Detection was performed using the monoclonal antibody A20 (kindly
+
concentrated in
-
provided by PD Dr. J. Kleinschmidt, DKFZ Heidelberg) that was biotinylated
+
a VivaSpin VS2002 (Sartorius Stedem) with a 10 kDa molecular weight
-
using a Biotinylation kit (Dojindo, Japan) and Streptavidin-HRP (Sigma-Aldrich).
+
cut-off to
-
The HRP presence was detected by the conversion of the substrate ABTS at 405
+
two milliliters and washed three to five times with 20 mM Bis-Tris
-
nm. The average of the non-template controls (NTC) was subtracted from the
+
buffer, pH 6.
-
sample data.</span></p>
+
The cell lysates were incubated with 250 units of Benzonase
-
 
+
(Sigma-Aldrich) to
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
remove contaminant genomic DNA and loaded on an ÄKTA purifier (GE
-
lang=EN-US style='font-size:12.0pt;line-height:200%'>&nbsp;</span></p>
+
Healthcare) equipped
-
 
+
with a Superdex 200 gel filtration column (GE Healthcare). Fractions
-
<span lang=EN-US style='font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"'><br
+
(500 µl)
-
clear=all style='page-break-before:always'>
+
around the void volume containing viral particles were collected and
-
</span>
+
used in a
-
 
+
sandwich ELISA. 96 well plates were coated with 200 ng Cetuximab
-
<p class=MsoNormal align=left style='margin-bottom:10.0pt;text-align:left;
+
(Imclone/Merck/Bristol-Myers
-
text-indent:0cm;line-height:115%'><span lang=EN-US>&nbsp;</span></p>
+
Squibb). Detection was performed using the monoclonal antibody A20
-
 
+
(kindly
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
provided by PD Dr. J. Kleinschmidt, DKFZ Heidelberg) that was
-
lang=EN-US>Results and Discussion:</span></p>
+
biotinylated
-
 
+
using a Biotinylation kit (Dojindo, Japan) and Streptavidin-HRP
-
<div align=center>
+
(Sigma-Aldrich).
-
 
+
The HRP presence was detected by the conversion of the substrate ABTS
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0 width=513
+
at 405
-
style='width:384.6pt;border-collapse:collapse;border:none'>
+
nm. The average of the non-template controls (NTC) was subtracted from
-
<tr style='height:305.8pt'>
+
the
-
  <td width=513 valign=top style='width:384.6pt;padding:0cm 5.4pt 0cm 5.4pt;
+
sample data.<br>
-
  height:305.8pt'>
+
<span style="font-size: 12pt; line-height: 200%;" lang="EN-US"></span> <br>
-
  <p class=MsoNormal align=center style='text-align:center;text-indent:0cm'><img
+
</p>
-
  width=421 height=722 src="!Word%20-%20for%20mergeII-Dateien/image008.gif"
+
<span lang="EN-US"></span>
-
  align=left hspace=12></p>
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
  </td>
+
align="left"><span lang="EN-US">
-
</tr>
+
<h2>Results and Discussion:</h2>
-
<tr style='height:15.45pt'>
+
</span></p>
-
  <td width=513 valign=top style='width:384.6pt;padding:0cm 5.4pt 0cm 5.4pt;
+
<div align="center">
-
  height:15.45pt'>
+
<table class="MsoTableGrid"
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
style="border: medium none ; width: 384.6pt; border-collapse: collapse;"
-
  lang=EN-US>A: Sandwich-ELISA scheme for the detection of Z34C-presenting
+
border="0" cellpadding="0" cellspacing="0" width="513">
-
  viral particles. Immobilization is achieved by binding a IgG molecule. Intact
+
<tbody>
-
  viral capsids can be specifically bound by the biotinylated A20 antibody
+
<tr style="height: 305.8pt;">
-
  which can be detected by Strepavidin-HRP</span></p>
+
<td style="padding: 0cm 5.4pt; width: 384.6pt; height: 305.8pt;"
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
valign="top" width="513">
-
  lang=EN-US>B: ELISA using the principle described in A for loop insertion
+
<p class="MsoNormal" style="text-align: center; text-indent: 0cm;"
-
  samples obtained by gel filtration chromatography of 453- and 587-Z34C
+
align="center"><img style="width: 421px; height: 722px;" alt=""
-
  particles. Undiluted and 10-fold diluted samples were employed</span></p>
+
src="https://static.igem.org/mediawiki/2010/2/23/Freiburg10_Z34C_affinity_data.png"
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
align="left" hspace="12"></p>
-
  lang=EN-US>C: ELISA signals obtained by absorbance measurements from B at 405
+
</td>
-
  nm, undiluted samples</span></p>
+
</tr>
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
<tr style="height: 15.45pt;">
-
  lang=EN-US>D: ELISA signals obtained by absorbance measurements from B at 405
+
<td style="padding: 0cm 5.4pt; width: 384.6pt; height: 15.45pt;"
-
  nm, diluted samples</span></p>
+
valign="top" width="513">
-
  </td>
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
</tr>
+
align="left"><span lang="EN-US">A: Sandwich-ELISA scheme for the
 +
detection of Z34C-presenting viral particles. Immobilization is
 +
achieved by binding a IgG molecule. Intact viral capsids can be
 +
specifically bound by the biotinylated A20 antibody which can be
 +
detected by Strepavidin-HRP</span></p>
 +
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
 +
align="left"><span lang="EN-US">B: ELISA using the principle described
 +
in A for loop insertion samples obtained by gel filtration
 +
chromatography of 453- and 587-Z34C particles. Undiluted and 10-fold
 +
diluted samples were employed</span></p>
 +
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
 +
align="left"><span lang="EN-US">C: ELISA signals obtained by
 +
absorbance measurements from B at 405 nm, undiluted samples</span></p>
 +
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
 +
align="left"><span lang="EN-US">D: ELISA signals obtained by
 +
absorbance measurements from B at 405 nm, diluted samples</span></p>
 +
</td>
 +
</tr>
 +
</tbody>
</table>
</table>
-
 
</div>
</div>
-
 
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
align="left"><span lang="EN-US">
-
lang=EN-US>&nbsp;</span></p>
+
<p style="text-align: justify;">Three samples of different viral
-
 
+
particles with insertions of the
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
antibody-binding motif Z34C were successfully purified by the gel
-
lang=EN-US>Three samples of different viral particles with insertions of the
+
filtration
-
antibody-binding motif Z34C were successfully purified by the gel filtration
+
chromatography. The fractions around the void volume were subsequently
-
chromatography. The fractions around the void volume were subsequently used in
+
used in
-
two different sandwich ELISAs. The first one aims at the detection of the
+
two different sandwich ELISAs. The first one aims at the detection of
-
particle’s ability to bind IgG-antibodies. The therapeutical antibody Cetuximab
+
the
-
was employed to test the affinity of the virus particles. As displayed in
+
particle’s ability to bind IgG-antibodies. The therapeutical antibody
-
figure 1A, only Z34C-presenting particles should be immobilized and only
+
Cetuximab
-
assembled viral capsid will be detected due to the affinity of the A20 antibody
+
was employed to test the affinity of the virus particles. As displayed
-
(as described above). Figure 1B shows that absorbance signal were obtained in
+
in
-
case of the 587KO-Z34C and 587KO-Z34C-spacer insertions. Loop 453-Z34C did not
+
figure 1A, only Z34C-presenting particles should be immobilized and
-
yield any significant absorbance signals. In addition, the assay was performed
+
only
-
with undiluted samples and those which were 10-fold diluted in PBST + 0.5 %
+
assembled viral capsid will be detected due to the affinity of the A20
-
BSA. Signal strengths in the undiluted ELISA samples indicated that the assay
+
antibody
-
was saturated, therefore the diluted sample data were used for evaluation. The
+
(as described above). Figure 1B shows that absorbance signal were
 +
obtained in
 +
case of the 587KO-Z34C and 587KO-Z34C-spacer insertions. Loop 453-Z34C
 +
did not
 +
yield any significant absorbance signals. In addition, the assay was
 +
performed
 +
with undiluted samples and those which were 10-fold diluted in PBST +
 +
0.5 %
 +
BSA. Signal strengths in the undiluted ELISA samples indicated that the
 +
assay
 +
was saturated, therefore the diluted sample data were used for
 +
evaluation. The
ABTS conversion indicates that highest amount of Z34C-presenting viral
ABTS conversion indicates that highest amount of Z34C-presenting viral
particles is present in the Äkta fractions 7-9 of the two different 587
particles is present in the Äkta fractions 7-9 of the two different 587
-
insertions. No viral particles with a binding affinity for the IgG antibody
+
insertions. No viral particles with a binding affinity for the IgG
-
were present in the 453 samples.</span></p>
+
antibody
-
 
+
were present in the 453 samples.</p>
-
<div align=center>
+
</span></p>
-
 
+
<div align="center">
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
+
<table class="MsoTableGrid"
-
style='border-collapse:collapse;border:none'>
+
style="border: medium none ; border-collapse: collapse;" border="0"
-
<tr style='height:593.75pt'>
+
cellpadding="0" cellspacing="0">
-
  <td width=424 valign=top style='width:318.25pt;padding:0cm 5.4pt 0cm 5.4pt;
+
<tbody>
-
  height:593.75pt'>
+
<tr style="height: 593.75pt;">
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><img
+
<td style="padding: 0cm 5.4pt; width: 318.25pt; height: 593.75pt;"
-
  width=410 height=793 src="!Word%20-%20for%20mergeII-Dateien/image009.gif"
+
valign="top" width="424">
-
  align=left hspace=12></p>
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
  </td>
+
align="left"><img style="width: 410px; height: 793px;" alt=""
-
</tr>
+
src="https://static.igem.org/mediawiki/2010/0/0b/Freiburg10_Z34C_titration_data.png"
-
<tr style='height:39.25pt'>
+
align="left" hspace="12"></p>
-
  <td width=424 valign=top style='width:318.25pt;padding:0cm 5.4pt 0cm 5.4pt;
+
</td>
-
  height:39.25pt'>
+
</tr>
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
<tr style="height: 39.25pt;">
-
  lang=EN-US>A: Sandwich-ELISA scheme for the detection of AAV-2 particles.
+
<td style="padding: 0cm 5.4pt; width: 318.25pt; height: 39.25pt;"
-
  Immobilization is achieved by binding to the A20 capture molecule which also
+
valign="top" width="424">
-
  acts as the biotinylated detection antibody after washing. Intact viral
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
  capsids can be specifically detected by Strepavidin-HRP</span></p>
+
align="left"><span lang="EN-US">A: Sandwich-ELISA scheme for the
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
detection of AAV-2 particles. Immobilization is achieved by binding to
-
  lang=EN-US>B: ELISA using the principle described in A for loop insertion
+
the A20 capture molecule which also acts as the biotinylated detection
-
  samples obtained by gel filtration chromatography of 453- and 587-Z34C
+
antibody after washing. Intact viral capsids can be specifically
-
  particles. Undiluted and 10-fold diluted samples were employed</span></p>
+
detected by Strepavidin-HRP</span></p>
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
  lang=EN-US>C: qPCR data for the CMV-promoter-based DRP-titer determination.
+
align="left"><span lang="EN-US">B: ELISA using the principle described
-
  Samples as in B</span></p>
+
in A for loop insertion samples obtained by gel filtration
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
chromatography of 453- and 587-Z34C particles. Undiluted and 10-fold
-
  lang=EN-US>D: ELISA signals obtained by absorbance measurements from B at 405
+
diluted samples were employed</span></p>
-
  nm, diluted samples</span></p>
+
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
-
  </td>
+
align="left"><span lang="EN-US">C: qPCR data for the
-
</tr>
+
CMV-promoter-based DRP-titer determination. Samples as in B</span></p>
 +
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
 +
align="left"><span lang="EN-US">D: ELISA signals obtained by
 +
absorbance measurements from B at 405 nm, diluted samples</span></p>
 +
</td>
 +
</tr>
 +
</tbody>
</table>
</table>
-
 
</div>
</div>
-
 
+
<p class="MsoNormal" style="text-align: justify; text-indent: 0cm;"
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
align="left">A second approach was conducted to
-
lang=EN-US>&nbsp;</span></p>
+
reveal the reason for the absence
-
 
+
of Z34C-presenting particles in case of the 453 insertion. The sandwich
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
ELISA,
-
lang=EN-US>A second approach was conducted to reveal the reason for the absence
+
-
of Z34C-presenting particles in case of the 453 insertion. The sandwich ELISA,
+
as shown in figure 2A, uses the A20 antibody to capture and detect all
as shown in figure 2A, uses the A20 antibody to capture and detect all
-
assembled viral capsids independent of the presence of a Z34C motif giving the
+
assembled viral capsids independent of the presence of a Z34C motif
-
so-called physical AAV titer (see figure 2D). To correlate these measurements,
+
giving the
-
we additionally conducted qPCR measurements to determine the amount of encapsidated
+
so-called physical AAV titer (see figure 2D). To correlate these
-
vector plasmids, the so-called DRP (DNAse-resistant particle) titer (see figure
+
measurements,
-
2C). Comparison reveals that both assays yielded a peak signal around the Äkta
+
we additionally conducted qPCR measurements to determine the amount of
-
fraction 8. The qPCR data indicated that all samples contain approximately 2 x
+
encapsidated
-
10^9 copies of the vector plasmid per milliliter. Assuming equal packaging
+
vector plasmids, the so-called DRP (DNAse-resistant particle) titer
-
efficiencies for the vector plasmids, all three loop insertion approaches
+
(see figure
-
contain comparable amounts of viral capsids. The sandwich-ELISA yielded a peak
+
2C). Comparison reveals that both assays yielded a peak signal around
-
around fraction eight for all three loop-insertion approaches. Since the signal
+
the Äkta
-
strength for the 587KO-Z34C samples is significantly higher, it can be assumed that
+
fraction 8. The qPCR data indicated that all samples contain
-
additionally to the affinity of the A20 antibody for assembled viral capsids,
+
approximately 2 x
-
the Z34C-containing viral particles add a high affinity for the Fc-part of the
+
10^9 copies of the vector plasmid per milliliter. Assuming equal
-
detection antibody. Hence the qPCR-titration only depends on the number of
+
packaging
-
encapsidated AAV-vector plasmids and not on the viral capsid and its degree of
+
efficiencies for the vector plasmids, all three loop insertion
-
modification, it is the more quantitative method of particle titration which
+
approaches
-
proved equal for all three loop insertion approaches.</span></p>
+
contain comparable amounts of viral capsids. The sandwich-ELISA yielded
-
 
+
a peak
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
around fraction eight for all three loop-insertion approaches. Since
-
lang=EN-US>&nbsp;</span></p>
+
the signal
-
 
+
strength for the 587KO-Z34C samples is significantly higher, it can be
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
assumed that
-
lang=EN-US>&nbsp;</span></p>
+
additionally to the affinity of the A20 antibody for assembled viral
-
 
+
capsids,
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm;
+
the Z34C-containing viral particles add a high affinity for the Fc-part
-
page-break-after:avoid'><span lang=EN-US>Summarizing, the insertion of a 34/39
+
of the
-
amino acid functional motif into the two most promising integration sites of
+
detection antibody. Hence the qPCR-titration only depends on the number
-
the AAV-2 capsid (see figure 3) revealed no integration of modified viral
+
of
-
capsid proteins (VP1-3) into assembled viral capsids for the 453 integration
+
encapsidated AAV-vector plasmids and not on the viral capsid and its
-
site. As also seen by the data obtained for the linker-containing insertion,
+
degree of
-
the 587 region tolerates insertions of at least 39 amino acids. For the 453
+
modification, it is the more quantitative method of particle titration
-
integration site, either the inserted Z34C motif loses its ability to bind IgG
+
which
-
molecules or the influence of the inserted motif causes strong structural
+
proved equal for all three loop insertion approaches.<span lang="EN-US">
-
changes that disturb the ability of the modified VP proteins to be integrated
+
<br>
-
into the virus capsid.</span></p>
+
</span></p>
-
 
+
<p class="MsoNormal"
-
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
+
style="text-align: left; text-indent: 0cm; page-break-after: avoid;"
-
 
+
align="left"><span lang="EN-US">
-
<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
+
<p style="text-align: justify;">Summarizing, the insertion of a 34/39
-
style='border-collapse:collapse;border:none'>
+
amino acid functional motif into the two most promising integration
-
<tr style='height:209.35pt'>
+
sites of
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt;
+
the AAV-2 capsid (see figure 3) revealed no integration of modified
-
  height:209.35pt'>
+
viral
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><img
+
capsid proteins (VP1-3) into assembled viral capsids for the 453
-
  border=0 width=571 height=269 id="Picture 15"
+
integration
-
  src="!Word%20-%20for%20mergeII-Dateien/image010.jpg"></p>
+
site. As also seen by the data obtained for the linker-containing
-
  </td>
+
insertion,
-
</tr>
+
the 587 region tolerates insertions of at least 39 amino acids. For the
-
<tr>
+
453
-
  <td width=636 valign=top style='width:477.3pt;padding:0cm 5.4pt 0cm 5.4pt'>
+
integration site, either the inserted Z34C motif loses its ability to
-
  <p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
+
bind IgG
-
  lang=EN-US>Loop insertion sites visualized in the 3D structure of a single
+
molecules or the influence of the inserted motif causes strong
-
  viral coat protein (VP3)</span></p>
+
structural
-
  </td>
+
changes that disturb the ability of the modified VP proteins to be
-
</tr>
+
integrated
 +
into the virus capsid.</p>
 +
</span></p>
 +
<span lang="EN-US">&nbsp;</span>
 +
<table class="MsoTableGrid"
 +
style="border: medium none ; border-collapse: collapse; text-align: left; margin-left: auto; margin-right: auto;"
 +
border="0" cellpadding="0" cellspacing="0">
 +
<tbody>
 +
<tr style="height: 209.35pt;">
 +
<td
 +
style="padding: 0cm 5.4pt; vertical-align: top; width: 477.3pt; height: 209.35pt;">
 +
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
 +
align="left"><img
 +
style="border: 0px solid ; width: 571px; height: 269px;" alt=""
 +
id="Picture 15"
 +
src="https://static.igem.org/mediawiki/2010/8/8f/Freiburg10_loop_insertion_sites.png"></p>
 +
</td>
 +
</tr>
 +
<tr>
 +
<td style="padding: 0cm 5.4pt; width: 477.3pt;" valign="top"
 +
width="636">
 +
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
 +
align="left"><span lang="EN-US">Loop insertion sites visualized in the
 +
3D structure of a single viral coat protein (VP3)</span></p>
 +
</td>
 +
</tr>
 +
</tbody>
</table>
</table>
 +
<p class="MsoNormal" style="text-align: left; text-indent: 0cm;"
 +
align="left"><span lang="EN-US">&nbsp;</span></p>
 +
</body>
 +
</html>
-
<p class=MsoNormal align=left style='text-align:left;text-indent:0cm'><span
 
-
lang=EN-US>&nbsp;</span></p>
 
-
</div>
+
{{:Team:Freiburg_Bioware/Footer}}

Latest revision as of 03:36, 28 October 2010

Loop Insertion

Modification of the Viral Capsid of the AAV2 using Viral Bricks

For therapeutical applications in human gene transfer, the broad tropism for heparan sulfate proteoglycan (HSPG) has to be knocked-out and a novel tropism has to be inserted. This retargeting can be achieved either by insertion of functional motifs into the two major surface exposed loops or by fusion of these motifs to the N-terminus of the viral coat proteins. The graphic on the right shows parts of the three-dimensional structure of a viral coat protein. The parts of the loop regions that are coded in the ViralBricks are shown in purple for the 453 loop and in blue for the 587 loop.

Three-dimensional representation of the AAV2 showing the amino acids of the 453 and 587 loops that are coded by the corresponding Viral Bricks.

Cloning of Viral Bricks into capsid coding parts

In order to make loop insertions more convenient the following restriction sites were inserted into all capsid coding parts and already existing restriction sites were removed from the constructs. The choice of these restriction sites was reasoned by enzyme performance, buffer compatibilities and the number of existing restriction sites that had to be removed at other positions. All restriction endonucleases were purchased from NEB.

His-Affinity tag

Schematic figure of His-affinity Tag insertion into the viral capsid

The insertion of a His-Affinity Tag into the exposed major surface loops of the viral vectors allows their specific affinity purification employing e.g. Ni-NTA affinity chromatography. This purification method was tested using the cell culture lysate of transfected AAV-293 cells that were either grown in DMEM supplemented with 10% FCS or in the serum-free GIBCO® FreeStyle™ 293 Expression Medium (Invitrogen). The usage of serum-free media is a technological modification meant to facilitate the production of pure viral vectors. Purified viral vectors are important for several applications such as animal models and biophysical characterizations. On the other hand, the elution of the His-tagged viral vectors allows also enrichment of transgene viral vectors. In order to answer the question if and to what degree viral vectors are transferred into the media, the cells were centrifugated, then divided into the pellet fraction and the supernatant. Physical cell lysis was performed for both fractions of the two produced batches (serum-free and FCS media) by performing four cycles of freeze and thaw.
 

Experimental setup for the purification of His-tag presenting viral particles produced by AAV-293 cells in DMEM or the protein- and animal-free Freestyle medium. Purified viral particles can be detected by ELISA using an anti-poly-Histidine antibody or qPCR for encapsidated vector plasmids, respectively

 

Material and Methods:

Transfection of the AAV-293 producer cells was performed in five 10 cm petri dishes with 3.6x10^6 cells, resulting in a confluency of about 70-80% according to the standard protocol either with cells grown in GIBCO® FreeStyle™ 293 Expression Medium (Invitrogen, protein- and animal-origin free) or in DMEM supplemented with 10% FCS (PAA). For transfection, the composite parts pCMV_VP123(587-His) and RepVP123(587-KO)_p5-TATA-less were used in an 1:1 ratio together with pHelper and [AAV2]-left-ITR_pCMV_betaglobin_mVenus_hGH_[AAV2]-right-ITR. Cells were spun down at 200 x g for five minutes and the samples were divided into the pellet and the supernatant fractions. Physical cell lysis was performed by four cycles of freeze and thaw for all four samples. The cell lysate / supernatant fractions were incubated with 800 µl of His-Affinity Gel (kindly provided by Zymo Resear    ch, USA) at 4 °C for 18 hours with 200 rpm constant agitation. The beads were then collected in 5 ml gravity-flow columns and washed five times with one column volume of PBS each. The His-affinity gel was subsequently washed with PBS, 25 mM Imidazole to remove unspecifically bound proteins. Elution was performed in an second step with PBS, 500 mM Imidazole to elute the His-tagged viral vectors. The genomic titer of the purified viral vectors was detected via q-PCR. In an ELISA, viral vectors were captured employing the monoclonal antibody A20 (kindly provided by PD Dr. J. Kleinschmidt, DKFZ, Heidelberg) that exclusively recognizes assembled AAV capsids. His-Tags present in assembled viral capsids were subsequently detected with an HRP-tagged secondary anti-His-Tag antibody (1:2000 diluted, A7058, Sigma). HRP presence was detected using the peroxidase substrate ABTS. Generation of blue-green color (absorption at 405 nm) was measured in a Tecan Sunrise plate reader. Sample data were blanked with the average of the non-template controls (NTC).

Results and Discussion

Presence of the His-affinity tag in the viral capsid was detected and the ELISA enabled quantification of the purification procedure efficiency. The absorbance measured for the elution fractions of the 1/10 diluted samples sums up to 2.3 for the DMEM- and 0.5 for the Free Style 293-grown cells, assigning the DMEM-grown cells a five times higher production efficiency. Comparison between the cell pellet and the supernatant fractions revealed that 70 - 80% of the viral particles can be found inside the producer cells.

According to these results, producer cells should be grown in complex media for in vitro and cell culture experiments. Use of serum-free produced viral vectors is recommended for mouse or other animal experiments and possible therapeutical applications where even the presence of traces amounts of fetal calf serum should be avoided. Combination with different purification approaches such as gel filtration chromatography using i.e. Superdex 200 columns (GE Healthcare) enables the production of highly purified viral vectors for several different applications.


A: Schematic overview of the sandwich ELISA for the detection of His-tagged viral particles

B: ELISA from viral particles produced by AAV-293 cells in DMEM or Free Style medium, divided into cell pellet and cell culture supernatant samples. The particles were purified using Ni-NTA affinity chromatography with Imidazole in PBS as washing and elution agent

C: Absorption measurements from plate shown in B. Undiluted Äkta fractions converted ABTS peroxidase substrate at 405 nm

D: As C, whereas Äkta fractions were 10-fold diluted


Biotinylation Acceptor Peptide (BAP)

http://partsregistry.org/wiki/images/a/a9/Freiburg10_ViralBrick_motif_BAP.png

Schematic overview of BAP insertion into AAV-2 viral capsids, followed by biotinylation and binding of streptavidin-coupled molecules

The BAP (Biotinylation Acceptor Peptide) included in the Virus Construction Kit is a 15 amino acid peptide identified by Schatz et al. (1993) in a library screening approach and published under the number #85. This peptide with the sequence GLNDIFEAQKIEWHE contains a central lysine residue that can be specifically biotinylated by the prokaryotic holoenzyme biotin synthetase, encoded by the BirA gene of E. coli. Specific biotinylation of this peptide sequence can be performed in vivo by cotransfecting a plasmid with the BirA gene as described for the AAV by Arnold et al. (2006) or by an in vitro coupling approach using the purified Escherichia coli enzyme biotin ligase (BirA).

Biotin molecules specifically coupled to the viral loops can either be used to attach Streptavidin-coupled molecules to the viral capsid or to chemically couple molecules with a reactive group to biotin. Consequently, the inserted motif can enable the visualization of single virus particles by coupling fluorophores to the virus capsid empowering further uses of the Virus Construction Kit in fundamental virological research. In addition, targeting molecules such as Streptavidin-coupled affinity molecules (i.e. Antibodies, Nanobodies or Affibodies) can be coupled for manifold targeting approaches.

Materials and Methods: 

Transfection of the AAV-293 producer cells was performed in five 10 cm petri dishes with 3.4x10^6 cells (grown in DMEM supplemented with 10% FCS) resulting in a confluence of 70-80% according to the standard protocol. Producer cells were harvested and together with the culture supernatant subjected to four cycles of freeze and thaw cell lysis. The cell lysate was centrifuged at 4000 rpm for 15 minutes and concentrated in a VivaSpin VS2002 column with 10 kDa molecular weight cut-off to yield two milliliters. Genomic DNA attached to the virus particles was degraded using 250 units of Benzonase (EC 3.1.30.2, Sigma-Aldrich) at 37 °C for one hour. The concentrated cell lysate was washed three times with 4 ml 20 mM bis-Tris buffer pH 6.0, 100 mM NaCl. From this concentrated sample, 500 µl were loaded on the ÄKTA purifier (GE Healthcare) equipped with a Superdex 200 gel filtration column (GE Healthcare). This purification is also described by Smith et al. (2003). Fractions around the void volume giving a UV absorbance peak were pooled and applied to a Amicon Ultra column (Millipore, size limit 100 kDa, 2 ml loading volume) and concentrated to 500 µl. This purified virus sample was washed four times with 10 mM Tris-buffer pH 8.0 buffer which is recommended for the BirA biotin ligase that was kindly provided by Avidity LCC (Colorado, USA).

The BAP-containing viral vector sample (500 µl) was mixed according to the manufacturer protocol with each 72 µl Biomix A, Biomix B and Biotin. To reach maximal biotinylation, a volume of 5 µl containing 25000 units of the biotin ligase BirA was added to the reaction mixture and incubated for 6 h at 30 °C. In order to remove unbound biotin, the biotinylated viral vectors were washed five times with 10 mM Tris buffer pH 8.0.

Biotinylation was verified with an ELISA as depicted in figure A. For the detection of successfully biotinylated viral vectors, MaxiSorp 96-well plates (Nunc) were coated with 200 ng monoclonal A20 antibody per well for eight hours at 4°C, and blocked over night with PBST + 0.5 % BSA. This plate was incubated for 1 h at room temperature with 100 µl of serial diluted viral vectors. After washing the plates three times, the recommended amount of Streptavidin-HRP conjugate (Sigma-Aldrich) was added to each well for 1 h at room temperature. Again, the plates were washed three times followed by detection of absorbance caused by converted ABTS substrate at 405 nm. Additionally, the genomic AAV-2 titer was determined by qPCR.

 

A: Schematic overview of the detection of BAP-presenting viral particles immobilized by A20 capture antibodies. Biotinylated capsids can be detected by streptavidin-coupled HRP

B: ELISA AAV-2 particles carrying a BAP insertion in loop 587 which can be specifically biotinylated in vitro

Results and Discussion:

As can be seen in figure B, biotinylation of assembled AAV particles was achieved with the dilution series ranging from 2- to 128-fold. Correlating this assay with the qPCR experiment for the detection of encapsidated vector plasmid (genomic titer using CMV-promoter primers) yields a value of 4.70E+07 DNase-resistant particles (DRP). Consequently, the presence of approximately 3.6x10^5 biotinylated DRPs can be detected using the described ELISA. Compared to the virus particle detection ELISA emploing A20 as capture- and detection antibody, the detection limit of the biotinylated viral capsids is about 10fold more sensitive. This may be explained by the higher affinity of strepavidin towards biotin relative to the A20 antibody affinity or multiple biotinylation of a single virus particle.


Miniaturized antibody binding domain (Z34C)

Schematic overview of Z34C insertion into AAV-2 viral capsids enabling antibody arming for therapy

The idea of this targeting approach is to utilize a minimized fragment of the Staphylococcal Protein A that was first described in Staphylococcus aureus. These gram-positive bacteria have evolved the 508 amino acid long protein A that has a high affinity for the Fc-domain of antibodies to protect itself from the immune system. Binding to the constant region of the antibodies is accomplished by the Z-Domain of Protein A that is 58-59 amino acids long, has alone a high affinity (Kd= 14,9 nM) for the antibodies and a three-helix bundle structure. In [Braisted & Wells; 1996] the authors reduced the secundary structure to an two-helix bundle. This size reduction has lead to an drastic reduction of the affinity for IgG (>10^5 fold) which could be recovered by 13 amino acid exchanges resulting in a 38 amino acid long peptide with an satisfying affinity for IgG (Kd = 185 nM) termed Z38. This binding domain was subsequently improved in [Starovasnik et al.; 1997] by the insertion of a disulfide bridge connecting the ends of the helices leading to the binding domain Z34C which shows an increased affinity for IgG (Kd = 20 nM).

 

Development of the Z34C motif, a miniaturized antibody binding motif


This engineered antibody binding domain of 34 amino acids was then inserted into capsids of different viral vectors amongst others also the AAV. In [Ried et al.; 2002] the Z34C domain was inserted at position 587 into the capsid of the AAV resulting in viral vector that can be targeted to different target cells without genetic engineering. This targeting approach was then improved in [Gigout et al.; 2005] by the creation of mosaic vectors that contain only ~25% of recombinant VP-Proteins what resulted in 4 to 5 orders of magnitude more infectiosity compared to all-mutant viruses

Material and Methods:

Transfection of the AAV-293 producer cells was performed for three different loop insertions of Z34C in each three 10 cm petri dishes with 3.4x10^6 cells resulting in a confluence of about 70-80%. For the transfection, either the composite parts pCMV_VP123(453-Z34C), pCMV_VP123(587KO- Z34C) or pCMV_VP123(587Ko- Z34C-Spacer) were cotransfected with pHelper, [AAV2]-left-ITR_pCMV_betaglobin_mVenus_hGH_[AAV2]-right-ITR and RepVP123(587KO). The producer cells were harvested with the culture supernatant and subjected to four cycles of freeze and thaw cell lysis. The cell lysate was centrifuged at 4000 rpm for 15 minutes and concentrated in a VivaSpin VS2002 (Sartorius Stedem) with a 10 kDa molecular weight cut-off to two milliliters and washed three to five times with 20 mM Bis-Tris buffer, pH 6. The cell lysates were incubated with 250 units of Benzonase (Sigma-Aldrich) to remove contaminant genomic DNA and loaded on an ÄKTA purifier (GE Healthcare) equipped with a Superdex 200 gel filtration column (GE Healthcare). Fractions (500 µl) around the void volume containing viral particles were collected and used in a sandwich ELISA. 96 well plates were coated with 200 ng Cetuximab (Imclone/Merck/Bristol-Myers Squibb). Detection was performed using the monoclonal antibody A20 (kindly provided by PD Dr. J. Kleinschmidt, DKFZ Heidelberg) that was biotinylated using a Biotinylation kit (Dojindo, Japan) and Streptavidin-HRP (Sigma-Aldrich). The HRP presence was detected by the conversion of the substrate ABTS at 405 nm. The average of the non-template controls (NTC) was subtracted from the sample data.

Results and Discussion:

A: Sandwich-ELISA scheme for the detection of Z34C-presenting viral particles. Immobilization is achieved by binding a IgG molecule. Intact viral capsids can be specifically bound by the biotinylated A20 antibody which can be detected by Strepavidin-HRP

B: ELISA using the principle described in A for loop insertion samples obtained by gel filtration chromatography of 453- and 587-Z34C particles. Undiluted and 10-fold diluted samples were employed

C: ELISA signals obtained by absorbance measurements from B at 405 nm, undiluted samples

D: ELISA signals obtained by absorbance measurements from B at 405 nm, diluted samples

Three samples of different viral particles with insertions of the antibody-binding motif Z34C were successfully purified by the gel filtration chromatography. The fractions around the void volume were subsequently used in two different sandwich ELISAs. The first one aims at the detection of the particle’s ability to bind IgG-antibodies. The therapeutical antibody Cetuximab was employed to test the affinity of the virus particles. As displayed in figure 1A, only Z34C-presenting particles should be immobilized and only assembled viral capsid will be detected due to the affinity of the A20 antibody (as described above). Figure 1B shows that absorbance signal were obtained in case of the 587KO-Z34C and 587KO-Z34C-spacer insertions. Loop 453-Z34C did not yield any significant absorbance signals. In addition, the assay was performed with undiluted samples and those which were 10-fold diluted in PBST + 0.5 % BSA. Signal strengths in the undiluted ELISA samples indicated that the assay was saturated, therefore the diluted sample data were used for evaluation. The ABTS conversion indicates that highest amount of Z34C-presenting viral particles is present in the Äkta fractions 7-9 of the two different 587 insertions. No viral particles with a binding affinity for the IgG antibody were present in the 453 samples.

A: Sandwich-ELISA scheme for the detection of AAV-2 particles. Immobilization is achieved by binding to the A20 capture molecule which also acts as the biotinylated detection antibody after washing. Intact viral capsids can be specifically detected by Strepavidin-HRP

B: ELISA using the principle described in A for loop insertion samples obtained by gel filtration chromatography of 453- and 587-Z34C particles. Undiluted and 10-fold diluted samples were employed

C: qPCR data for the CMV-promoter-based DRP-titer determination. Samples as in B

D: ELISA signals obtained by absorbance measurements from B at 405 nm, diluted samples

A second approach was conducted to reveal the reason for the absence of Z34C-presenting particles in case of the 453 insertion. The sandwich ELISA, as shown in figure 2A, uses the A20 antibody to capture and detect all assembled viral capsids independent of the presence of a Z34C motif giving the so-called physical AAV titer (see figure 2D). To correlate these measurements, we additionally conducted qPCR measurements to determine the amount of encapsidated vector plasmids, the so-called DRP (DNAse-resistant particle) titer (see figure 2C). Comparison reveals that both assays yielded a peak signal around the Äkta fraction 8. The qPCR data indicated that all samples contain approximately 2 x 10^9 copies of the vector plasmid per milliliter. Assuming equal packaging efficiencies for the vector plasmids, all three loop insertion approaches contain comparable amounts of viral capsids. The sandwich-ELISA yielded a peak around fraction eight for all three loop-insertion approaches. Since the signal strength for the 587KO-Z34C samples is significantly higher, it can be assumed that additionally to the affinity of the A20 antibody for assembled viral capsids, the Z34C-containing viral particles add a high affinity for the Fc-part of the detection antibody. Hence the qPCR-titration only depends on the number of encapsidated AAV-vector plasmids and not on the viral capsid and its degree of modification, it is the more quantitative method of particle titration which proved equal for all three loop insertion approaches.

Summarizing, the insertion of a 34/39 amino acid functional motif into the two most promising integration sites of the AAV-2 capsid (see figure 3) revealed no integration of modified viral capsid proteins (VP1-3) into assembled viral capsids for the 453 integration site. As also seen by the data obtained for the linker-containing insertion, the 587 region tolerates insertions of at least 39 amino acids. For the 453 integration site, either the inserted Z34C motif loses its ability to bind IgG molecules or the influence of the inserted motif causes strong structural changes that disturb the ability of the modified VP proteins to be integrated into the virus capsid.

 

Loop insertion sites visualized in the 3D structure of a single viral coat protein (VP3)